• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    BioArctic's Capital Markets Day 2025 - entering a new era of growth

    6/2/25 4:47:00 AM ET
    $B
    Precious Metals
    Basic Materials
    Get the next $B alert in real time by email

    STOCKHOLM, June 2, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today welcomes investors, analysts and financial media to the company's Capital Markets Day. The event, which starts at 10:30 CET, will be broadcast live online.

    Over the past 20 years, BioArctic has built a thriving company based on a foundation of solid science and innovation, strong finances and an organization with well-educated staff and a value-driven corporate culture.

    At the Capital Markets Day, management will outline BioArctic's ambitions for 2030 which focuses on building Sweden's next major pharmaceutical company. This will be achieved by:

    • building a balanced and broad pipeline with projects in all stages of development,
    • adding additional successful global partnerships, and
    • establishing Leqembi® as a treatment for Alzheimer's disease in the Nordics
    • ensuring finances that allow for both investing in growth while giving recurring dividends to shareholders.

    To achieve this, the company will accelerate innovation into a broader area of severe brain diseases, proactively work with business development to maximize the value of each project, and work to ensure a successful launch of Leqembi in the Nordic region.

    The presentation for the Capital Markets Day can be found on https://www.bioarctic.com/en/investors/conference-presentations/.

    A recording of the Capital Markets Day will be available later today on BioArctic's website.

    AGENDA

    10:30 BioArctic today and tomorrow

    Precision neurology and severe brain disease experiencing unprecedented opportunities for innovation. Chief Executive Officer Gunilla Osswald will discuss how BioArctic is positioning itself to capture these global possibilities and outline the company's ambitions toward 2030.

    11:00 Financials

    Following the recent license agreement with Bristol Myers Squibb and with continuous royalties from Leqembi sales, BioArctic expects to achieve profitability from this year onwards. Anders Martin-Löf, Chief Financial Officer, will outline what this strengthened financial position means for shareholders and BioArctic's future opportunities.

    11:20 R&D Strategy

    Based on the same principle as Leqembi, BioArctic has built a project portfolio with selective antibodies targeting aggregated forms of misfolded proteins in the brain. Chief R&D Officer Johanna Fälting will outline the overarching research strategy and explain how BioArctic's integrated antibody and BrainTransporter™ platforms create opportunities across several disease areas.

    11:50 Q&A

    12:10 Lunch

    13:00 Leqembi

    Leqembi is the first fully approved disease-modifying treatment for early Alzheimer's disease, marking a transformational shift in the treatment landscape. Anna-Kaija Grönblad, Chief Commercial Officer, will discuss this evolving paradigm, provide insights into global and European market developments, and outline BioArctic's preparations for the Nordic launch.

    13:20 Key opinion leader: Disease modifying treatment for Alzheimer's disease in clinical use

    Since the initial approval of Leqembi in the United States in January 2023, clinicians have gained important real-world experience with this groundbreaking therapy for early Alzheimer's disease. Professor Lawrence S. Honig from Columbia University's Department of Neurology will present clinical insights from US practice and discuss the practical challenges and opportunities of implementing this new treatment paradigm.

    14:00 Q&A

    14:15 BrainTransporter-technology

    Biological drugs hold enormous potential for treating brain diseases, but the blood-brain barrier has historically prevented their effective delivery. Chief Scientific Officer Per-Ola Freskgård will present how BioArctic's breakthrough BrainTransporter technology can deliver antibodies with up to 70 times greater brain exposure and superior distribution and discuss the commercial opportunities this proprietary platform creates.

    14:55 Exidavnemab

    BioArctic's antibody exidavnemab targets alpha-synuclein, a key protein involved in multiple neurodegenerative conditions. Gabrielle Åhlberg Hillert, Chief Medical Officer, will provide an update on the Phase 2 program, explain how exidavnemab differentiates from other late-stage antibodies, and discuss how it could address significant unmet medical needs in alpha-synuclein diseases such as Parkinson's disease, Multiple System Atrophy, and Lewy body dementia.

    15.15 Q&A

    15.30 Concluding remarks

    Short summary by Gunilla Osswald, Chief Executive Officer

    The information was released for public disclosure, through the agency of the contact persons below, on June 2, 2025, at 10:30 CET.

    For further information, please contact: 

    Oskar Bosson, VP Communications and Investor Relations

    E-mail: [email protected]

    Telephone: +46 70 410 71 80

    Charlotte af Klercker, Senior Director Sustainability and Communications

    E-mail: [email protected]

    Telephone: +46 73 515 09 70

    About BioArctic AB

    BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) – the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit www.bioarctic.com.

    This information was brought to you by Cision http://news.cision.com

    https://news.cision.com/bioarctic/r/bioarctic-s-capital-markets-day-2025---entering-a-new-era-of-growth,c4157690

    The following files are available for download:

    https://mb.cision.com/Main/9978/4157690/3480820.pdf

    BioArctic’s Capital Markets Day 2025 â€" entering a new era of growth

    Cision View original content:https://www.prnewswire.com/news-releases/bioarctics-capital-markets-day-2025--entering-a-new-era-of-growth-302470540.html

    SOURCE BioArctic

    Get the next $B alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $B

    DatePrice TargetRatingAnalyst
    4/18/2024$35.00 → $45.00Neutral → Buy
    DA Davidson
    10/11/2022Peer Perform
    Wolfe Research
    4/11/2022$42.00Overweight → Neutral
    Alembic Global Advisors
    More analyst ratings

    $B
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Barnes Group Inc. (Amendment)

      SC 13D/A - BARNES GROUP INC (0000009984) (Subject)

      3/7/24 9:15:35 AM ET
      $B
      Precious Metals
      Basic Materials
    • SEC Form SC 13G/A filed by Barnes Group Inc. (Amendment)

      SC 13G/A - BARNES GROUP INC (0000009984) (Subject)

      2/14/24 6:06:48 AM ET
      $B
      Precious Metals
      Basic Materials
    • SEC Form SC 13G/A filed by Barnes Group Inc. (Amendment)

      SC 13G/A - BARNES GROUP INC (0000009984) (Subject)

      2/13/24 5:00:45 PM ET
      $B
      Precious Metals
      Basic Materials

    $B
    Leadership Updates

    Live Leadership Updates

    See more
    • Guidewire Software Set to Join S&P MidCap 400; Arrowhead Pharmaceuticals to Join S&P SmallCap 600

      NEW YORK, Jan. 22, 2025 /PRNewswire/ -- Guidewire Software Inc. (NYSE:GWRE) will replace Arrowhead Pharmaceuticals Inc. (NASD: ARWR) in the S&P MidCap 400, and Arrowhead Pharmaceuticals will replace Barnes Group Inc. (NYSE:B) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, January 27. S&P 500 constituent Apollo Global Management Inc. (NYSE:APO) is acquiring Barnes Group in a deal expected to be completed soon pending final conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector January 27, 2025 S&P MidCap 400 Addition Guidewi

      1/22/25 5:54:00 PM ET
      $APO
      $ARWR
      $B
      $GWRE
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Barnes Announces Update to Board of Directors

      Announces Planned Retirements of Chairman Thomas O. Barnes and Lead Independent Director Mylle H. Mangum, and appointment of Richard Hipple as Chair Elect Appoints Irenic Capital Management Co-Founder Adam Katz to the Board Enters into Cooperation Agreement with Irenic Capital Management Barnes Group Inc. (NYSE:B), a global provider of highly engineered products, differentiated industrial technologies, and innovative solutions, today announced the planned retirements of Chairman Thomas O. Barnes and Lead Independent Director Mylle H. Mangum, consistent with the Company's corporate governance retirement policy, effective at the Company's Annual Meeting of Stockholders in May 2024. Mr.

      3/5/24 4:15:00 PM ET
      $B
      $LMT
      $SPR
      Precious Metals
      Basic Materials
      Military/Government/Technical
      Industrials
    • Barnes Group Inc. Appoints Neal J. Keating to Board of Directors

      Barnes Group Inc. (NYSE:B), a global provider of highly engineered products, differentiated industrial technologies, and innovative solutions, today announced the appointment of Neal J. Keating to the Company's Board of Directors, effective February 9, 2023. Mr. Keating has also been appointed to the Company's Corporate Governance Committee. "We are pleased to welcome Neal to our Board of Directors," said Thomas O. Barnes, Chairman of the Board, Barnes Group Inc. "Neal brings extensive public company and board experience, and importantly he expands the Board's capabilities through his significant leadership experience in the aerospace industry, which aligns well with our growing Barnes Aer

      2/9/23 4:15:00 PM ET
      $B
      Precious Metals
      Basic Materials

    $B
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Next Gold Powerhouse Emerges as Prices Break Records

      NetworkNewsWire Editorial Coverage NEW YORK, June 4, 2025 /PRNewswire/ -- As gold surges to record highs above $3,000+ per ounce in May 2025 — outpacing the S&P 500, NASDAQ and even bitcoin—Wall Street's focus is shifting. With U.S. debt-to-GDP now exceeding 120% and real interest rates still historically negative, gold has reaffirmed its role as the market's most reliable hedge. But for institutional investors, bullion and ETFs aren't enough anymore. What they want now is leverage, scalability and cash flow. That's why the spotlight is turning toward a new class of near-term gold producers: companies with clean balance sheets, high internal rates of return (IRR) and operational models desig

      6/4/25 8:30:00 AM ET
      $AEM
      $B
      $BHP
      $WPM
      Precious Metals
      Basic Materials
      Coal Mining
      Energy
    • Barrick Completes Sale of 50% Interest in the Donlin Gold Project

      All amounts expressed in U.S. dollars TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Barrick Mining Corporation (NYSE:B) (TSX:ABX) announced today that it has completed the divestiture of its 50% interest in the Donlin Gold Project in Alaska to affiliates of Paulson Advisers LLC and NOVAGOLD Resources Inc. ((NYSE American, TSX:NG) for $1 billion in cash. Enquiries:Investor and Media RelationsKathy du Plessis+44 20 7557 7738Email: [email protected] Website: www.barrick.com

      6/3/25 6:02:57 PM ET
      $B
      Precious Metals
      Basic Materials
    • Next Gold Powerhouse Emerges as Prices Break Records

      NetworkNewsWire Editorial Coverage NEW YORK, June 2, 2025 /PRNewswire/ -- As gold surges to record highs above $3,000+ per ounce in May 2025 — outpacing the S&P 500, NASDAQ and even bitcoin—Wall Street's focus is shifting. With U.S. debt-to-GDP now exceeding 120% and real interest rates still historically negative, gold has reaffirmed its role as the market's most reliable hedge. But for institutional investors, bullion and ETFs aren't enough anymore. What they want now is leverage, scalability and cash flow. That's why the spotlight is turning toward a new class of near-term gold producers: companies with clean balance sheets, high internal rates of return (IRR) and operational models desig

      6/2/25 8:30:00 AM ET
      $AEM
      $B
      $BHP
      $WPM
      Precious Metals
      Basic Materials
      Coal Mining
      Energy

    $B
    SEC Filings

    See more
    • SEC Form 15-12G filed by Barnes Group Inc.

      15-12G - BARNES GROUP INC (0000009984) (Filer)

      2/6/25 9:14:41 AM ET
      $B
      Precious Metals
      Basic Materials
    • SEC Form S-8 POS filed by Barnes Group Inc.

      S-8 POS - BARNES GROUP INC (0000009984) (Filer)

      1/27/25 10:53:20 AM ET
      $B
      Precious Metals
      Basic Materials
    • SEC Form S-8 POS filed by Barnes Group Inc.

      S-8 POS - BARNES GROUP INC (0000009984) (Filer)

      1/27/25 10:53:23 AM ET
      $B
      Precious Metals
      Basic Materials

    $B
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mangum Mylle H bought $1,912 worth of shares (67 units at $28.65), increasing direct ownership by 0.25% to 26,367 units (SEC Form 4)

      4 - BARNES GROUP INC (0000009984) (Issuer)

      12/12/23 3:48:02 PM ET
      $B
      Precious Metals
      Basic Materials
    • Manner Hans-Peter bought $1,138,815 worth of shares (50,000 units at $22.78), increasing direct ownership by 311% to 66,079 units (SEC Form 4)

      4 - BARNES GROUP INC (0000009984) (Issuer)

      11/9/23 3:12:45 PM ET
      $B
      Precious Metals
      Basic Materials
    • Acker Marian bought $45,023 worth of shares (2,000 units at $22.51), increasing direct ownership by 7% to 32,599 units (SEC Form 4)

      4 - BARNES GROUP INC (0000009984) (Issuer)

      11/7/23 4:37:48 PM ET
      $B
      Precious Metals
      Basic Materials

    $B
    Financials

    Live finance-specific insights

    See more
    • Next Gold Powerhouse Emerges as Prices Break Records

      NetworkNewsWire Editorial Coverage NEW YORK, June 4, 2025 /PRNewswire/ -- As gold surges to record highs above $3,000+ per ounce in May 2025 — outpacing the S&P 500, NASDAQ and even bitcoin—Wall Street's focus is shifting. With U.S. debt-to-GDP now exceeding 120% and real interest rates still historically negative, gold has reaffirmed its role as the market's most reliable hedge. But for institutional investors, bullion and ETFs aren't enough anymore. What they want now is leverage, scalability and cash flow. That's why the spotlight is turning toward a new class of near-term gold producers: companies with clean balance sheets, high internal rates of return (IRR) and operational models desig

      6/4/25 8:30:00 AM ET
      $AEM
      $B
      $BHP
      $WPM
      Precious Metals
      Basic Materials
      Coal Mining
      Energy
    • Next Gold Powerhouse Emerges as Prices Break Records

      NetworkNewsWire Editorial Coverage NEW YORK, June 2, 2025 /PRNewswire/ -- As gold surges to record highs above $3,000+ per ounce in May 2025 — outpacing the S&P 500, NASDAQ and even bitcoin—Wall Street's focus is shifting. With U.S. debt-to-GDP now exceeding 120% and real interest rates still historically negative, gold has reaffirmed its role as the market's most reliable hedge. But for institutional investors, bullion and ETFs aren't enough anymore. What they want now is leverage, scalability and cash flow. That's why the spotlight is turning toward a new class of near-term gold producers: companies with clean balance sheets, high internal rates of return (IRR) and operational models desig

      6/2/25 8:30:00 AM ET
      $AEM
      $B
      $BHP
      $WPM
      Precious Metals
      Basic Materials
      Coal Mining
      Energy
    • BioArctic's Capital Markets Day 2025 - entering a new era of growth

      STOCKHOLM, June 2, 2025 /PRNewswire/ -- BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) today welcomes investors, analysts and financial media to the company's Capital Markets Day. The event, which starts at 10:30 CET, will be broadcast live online. Over the past 20 years, BioArctic has built a thriving company based on a foundation of solid science and innovation, strong finances and an organization with well-educated staff and a value-driven corporate culture. At the Capital Markets Day, management will outline BioArctic's ambitions for 2030 which focuses on building Sweden's next major pharmaceutical company. This will be achieved by: building a balanced and broad pipeline with projects i

      6/2/25 4:47:00 AM ET
      $B
      Precious Metals
      Basic Materials

    $B
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Katz Adam J disposed of 641,163 shares and returned $91,940,098 worth of shares to the company (1,935,581 units at $47.50), closing all direct ownership in the company (SEC Form 4)

      4 - BARNES GROUP INC (0000009984) (Issuer)

      1/29/25 8:52:13 PM ET
      $B
      Precious Metals
      Basic Materials
    • President and CEO Hook Thomas J disposed of 187,500 shares and returned $21,850,522 worth of shares to the company (460,011 units at $47.50), closing all direct ownership in the company (SEC Form 4)

      4 - BARNES GROUP INC (0000009984) (Issuer)

      1/27/25 1:07:10 PM ET
      $B
      Precious Metals
      Basic Materials
    • Director Manner Hans-Peter returned $22,388,317 worth of shares to the company (471,333 units at $47.50), closing all direct ownership in the company (SEC Form 4)

      4 - BARNES GROUP INC (0000009984) (Issuer)

      1/27/25 1:08:39 PM ET
      $B
      Precious Metals
      Basic Materials

    $B
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Barnes Group upgraded by DA Davidson with a new price target

      DA Davidson upgraded Barnes Group from Neutral to Buy and set a new price target of $45.00 from $35.00 previously

      4/18/24 7:26:23 AM ET
      $B
      Precious Metals
      Basic Materials
    • Wolfe Research initiated coverage on Barnes Group

      Wolfe Research initiated coverage of Barnes Group with a rating of Peer Perform

      10/11/22 7:16:00 AM ET
      $B
      Precious Metals
      Basic Materials
    • Barnes Group downgraded by Alembic Global Advisors with a new price target

      Alembic Global Advisors downgraded Barnes Group from Overweight to Neutral and set a new price target of $42.00

      4/11/22 8:41:22 AM ET
      $B
      Precious Metals
      Basic Materials